RIO DE JANEIRO, BRAZIL - The Brazilian Health Regulatory Agency (ANVISA) unanimously approved on Tuesday, April 20th, the emergency use of the monoclonal antibodies cocktail against Covid-19, produced by the company Regeneron and marketed by pharmaceutical company Roche.
It is the second drug against Covid-19 approved by ANVISA for use in Brazil. The first was remdesivir, on March 12th this year. The cocktail called REGN-COV2 contains a combination of the experimental monoclonal antibodies casirivimab and imdevimab.
The drug is administered intravenously, its use is restricted to hospitals, and sale is prohibited. The drug does not replace the Covid . . .
To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed? Login Here